Selected publications:

1.                  Loomba R, Lutchman GA, Kleiner D, Feld J, Borg B, Modi A, Premkumar A, Sumner A, Liang TJ, and Hoofnagle JH. Clinical Trial: A pilot study of metformin for the treatment of nonalcoholic steatohepatitis. Aliment Pharmacol Ther 2009; 29(2): 172-182.

2.                  Loomba R, Kleiner DE, and Hoofnagle JH. Mechanism of action of metformin in nonalcoholic steatohepatitis. Aliment Pharmacol Thera 2009; 29 (5): 603-604.

3.                  Stein L and Loomba R. Drug targets for hepatitis B virus. Infect Disord Drug Targets 2009; 9(2):105-16.

4.                  Loomba R, Wesley B, Bain A*, Csako G, Pucino F. Role of flouroquinolones in primary prophylaxis of spontaneous bacterial peritinotis: Meta-analysis. Clin Gastroentrol Hepatol 2009; 7(4):487-93.

5.                  Loomba R, Sirlin CB, Schwimmer JB and Lavine JE. Advances in pediatric nonalcoholic fatty liver disease. Hepatology 2009; 50(4):1282-93.

6.                  Palmore TN, Shah NL, Loomba R, Borg BB, Lopatin U, Feld JJ, Khokar F, Lutchman G, Kleiner DE, Young N, Childs R, Barrett JA, Liang TJ, Hoofnagle JH, Heller T. Reactivation of hepatitis B with reappearance of hepatitis B surface antigen after chemotherapy and immune suppression. Clin Gastroenetrol Hepatol 2009; 7(10):1130-7.

7.                  Loomba R, Bettencourt R, and Barrett-Connor E. Synergistic association between alcohol intake and body mass index with serum alanine and aspartate aminotransferase levels in older adults: The Rancho Bernardo Study. Aliment Pharmacol Ther. 2009; 30 (11-12):1137-49.

8.                  Stein LS*, Dong MH*, and Loomba R. Insulin Sensitizers in Nonalcoholic Fatty Liver Disease and Steatohepatitis: Current Status. Adva Ther 2009; 26(10):893-907.

9.                  Rotman Y, Borg BB, Soza A, Feld JJ, Modi AA, Loomba R, Lutchman G, Rivera E, Doo E, Ghany MG, Heller T, Neumann AU, Liang TJ, Hoofnagle JH. Clinical trial: low- and standard-dose peginterferon alfa-2a for chronic hepatitis C, genotype 2 or 3 - efficacy, tolerability, viral kinetics and cytokine response. Aliment Pharmacol Ther. 2010;31(9):1018-27.

10.              Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR. NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;6;362(18):1675-85.

11.              Loomba R, Rao F, Zhang L, Khandrika S, Ziegler M, Brenner DA, and O'Connor DT. Genetic covariance between gamma-glutamyl transpeptidase and fatty liver risk factors: role of beta2-adrenergic receptor genetic variation in twins. Gastroenterology. 2010;139(3):836-45.

12.              Loomba R, Yang YI, Su J, Brenner DA, Iloeje U, and Chen CJ. Obesity and alcohol synergize to increase the risk of incident hepatocellular carcinoma in men. Clin Gastroenterol Hepatol. 2010; 8(10):891-8, 898.

13.              Chalasani NP, Guo X, Loomba R, Mark GO, Haritunians T, Kwon S, Jinrui C, Kent TD, Wilson L; Cummings WO, Chen IY, and Rotter JI. Genome-wide association scan (GWAS) of patients with histologically characterized nonalcoholic fatty liver disease (NAFLD). Gastroenterology 2010; 139(5):1567-76.

14.              Dong M*, Bettencourt R, Barrett-Connor EB, and Loomba R. Alanine Aminotransferase decreases with age: The Rancho Bernardo Study. PLoS One. 2010 Dec 8;5(12):e14254

15.              Loomba R, McBurney R, Vanessa-Williams, Park Y, Barbara Rehermann, Alter H, Liang TJ, Hoofnagle JH and Heller T. Acute hepatitis C: Clinical presentation, laboratory findings, and treatment outcomes. Aliment Pharmacol Ther. 2011; 33(5):559-65.

16.              Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA; NASH Clinical Research Network (CRN). Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology. 2011; 53(3):810-20.

17.              Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, Abrams SH, Scheimann AO, Sanyal AJ, Chalasani N, Tonascia J, Ünalp A, Clark JM, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR; Nonalcoholic Steatohepatitis Clinical Research Network. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial.  JAMA. 2011; 305(16):1659-68.

18.              Wassel CL, Loomba R, Ix JH, Allison MA, Denenberg JO, Criqui MH. Family history of peripheral artery disease is associated with prevalence and severity of peripheral artery disease the San Diego population study. J Am Coll Cardiol. 2011; 58(13):1386-92.

19.              Dong M*, Bettencourt R, Brenner DA, Barrett-Connor EB, and Loomba R. Serum Levels of Alanine Aminotransferase Decrease with Age in Longitudinal Analysis. Clin Gastroenterol Hepatol. 2012; 10(3):285-290.

20.              Boettcher E*, Csako G, Pucino F, Wesley R, and Loomba R. Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with nonalcoholic steatohepatitis. Aliment Pharmacol Ther. 2012; 35(1):66-75.

21.              Lee JK*, Bettencourt R, Brenner DA, Le TA*, Barrett-Connor E , and Loomba R. Association between serum interleukin-6 concentrations and mortality in older adults: The Rancho Bernardo Study. PLoS One. 2012;7(4):e34218.

22.              Le TA*, Chen J, Changchien C, Peterson M, Kono Y, Patton H, Cohen BL*, Brenner DA, Sirlin C and Loomba R for the San Diego NAFLD Research Consortium (SINC). Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: A randomized controlled trial. Hepatology. 2012 Sep;56(3):922-932

23.              Loomba R, Yang YI, Iloeje U, Jun Su, Brenner DA, Barrett-Connor E and Chen CJ. Synergism between obesity and alcohol in increasing the risk of hepatocellular carcinoma: a prospective cohort study. Am J Epidemiol. 2013 Feb 15;177(4):333-42

24.              Loomba R, Abraham MB, Unalp A, Wilson L, Lavine JE, Doo E, Bass M, and the NASH Clinical Research Network. Association between diabetes, family history of diabetes and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology. 2012 Sep; 56 (3):943-951.

25.              Loomba R. Who should undergo a liver biopsy in NAFLD? AGA Perspectives 2012. Vol 8. No.3: 20-21

26.              Bambha K, Belt P, Abraham M, Wilson LA, Pabst M, Ferrell L, Unalp-Arida A, Bass N; Nonalcoholic Steatohepatitis Clinical Research Network Research Group. Ethnicity and nonalcoholic fatty liver disease. Hepatology 2012; 55(3):769-80.

27.              Permutt Z*, Le TA*, Peterson MR, Seki E, Brenner DA, Sirlin C, Loomba R. Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease - MRI accurately quantifies hepatic steatosis in NAFLD. Aliment Pharmacol Ther. 2012 Jul;36(1):22-9

28.              Le TA*, Loomba R. Management of nonalcoholic fatty liver disease and steatohepatitis. J Clin Exp Hepatology. 2012 Jun; 2(2): 156-73.

29.              Noureddin M*, and Loomba R. Indications for liver biopsy & Non-invasive biomarkers in nonalcoholic fatty liver disease. Clinical Liver Disease. September 2012: 1, 4, 103–106

30.              Abecassis M, Bridges ND, Clancy CJ, Dew MA, Eldadah B, Englesbe MJ, Flessner MF, Frank JC, Friedewald  J, Gill J, Gries C, Halter JB, Hartmann EL, Hazzard WR, Horne FM, Hosenpud J,  Jacobson JP, Kasiske BL, Lake J, Loomba R, Malani PN, T.M. Moore TM, Murray A, Nguyen M-H, Powe NR, Reese PP, Reynolds H, Samaniego MD, Schmader KE, Segev DL, Shah AS, Singer LG, Sosa JA, Stewart ZA, Tan JC, Williams WW, Zaas DW, High KP. Solid Organ Transplantation in Older Adults: Current Status and Future Research. Am J Transplant. 2012 Oct;12(10):2608-22

31.              Rose SC, Kikolski SG, Gish RG, Kono Y, Loomba R, Hemming AW, Wallace MJ; On behalf of the Society of Interventional Radiology. Society of interventional radiology critique and commentary on the cochrane report on transarterial (chemo) embolization. Hepatology. 2013 Apr;57(4):1675-6

32.              Hwang JP, Vierling JM, Zelenetz AD, Lackey SC, Loomba R. Hepatitis B virus management to prevent reactivation after chemotherapy: a review. Support Care Cancer. 2012 Nov;20(11):2999-3008

33.              Zarrinpar A* and Loomba R. Systematic Review: The Emerging Interplay Between Bile Acids, Gastrointestinal Tract, and Incretins in the Pathogenesis of Diabetes and Nonalcoholic Fatty Liver Disease. Aliment Pharmacol Ther. 2012 Nov;36(10):909-21

34.              Loomba R, Doycheva I*, Bettencourt R, Cohen B*, Wassel C, Brenner DA, and Barrett-Connor E. Serum gamm-glutamyltranspeptidase predicts all-cause, cardiovascular and liver mortality in older adults. J Clin Exp Hepatol. 2013 Mar 1;3(1):4-11

35.              Doycheva I*, Patel N*, Peterson M, Loomba R. Prognostic implication of liver histology in patients with nonalcoholic fatty liver disease in diabetes. J Diabetes Complications. 2013 May-Jun;27(3):293-300

36.              Patel N*, Peterson MR, Brenner DA, Heba E, Sirlin C, Loomba R. Association between novel MRI-estimated pancreatic fat and liver histology-determined steatosis and fibrosis in nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2013 Mar;37(6):630-9.

37.              Patel NS*, Loomba R. Commentary: non-alcoholic fatty pancreas -- toward an uncharted territory; authors' reply. Aliment Pharmacol Ther. 2013 May;37(9):916-7

38.              Tang A, Tan J, Sun M, Hamilton G, Bydder M, Wolfson T, Gamst AC, Middleton M, Brunt EM, Loomba R, Lavine JE, Schwimmer JB, Sirlin CB. Nonalcoholic Fatty Liver Disease: MR Imaging of Liver Proton Density Fat Fraction to Assess Hepatic Steatosis. Radiology. 2013 May;267(2):422-431

39.              Yang L, Inokuchi S, Roh YS, Song J, Loomba R, Park EJ, Seki E. Transforming Growth Factor-β Signaling in Hepatocytes Promotes Hepatic Fibrosis and Carcinogenesis in Mice with Hepatocyte-Specific Deletion of TAK1. Gastroenterology. 2013 May; 144(5):1042-1054.

40.              Hoofnagle JH, Van Natta ML, Kleiner DE, Clark JM, Kowdley KV, Loomba R, Neuschwander-Tetri BA, Sanyal AJ, Tonascia J; the Non-alcoholic Steatohepatitis Clinical Research Network (NASH CRN). Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2013 Jul;38(2):134-43.

41.              Jensky NE, Allison MA, Loomba R, Carnethon MR, de Boer IH, Budoff MJ, Burke GL, Criqui MH, Ix JH. Null association between abdominal muscle and calcified atherosclerosis in community-living persons without clinical cardiovascular disease: The multi-ethnic study of atherosclerosis. Metabolism. 2013 Nov;62(11):1562-9

42.              Loomba R and Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013 Nov;10(11):686-90

43.              Patel NS*, Peterson MR, Lin GY, Feldstein A, Schnabl A, Bettencourt R, Seki E, Sirlin CB, and Loomba R. Insulin resistance increases MRI-estimated pancreatic fat in nonalcoholic fatty liver disease and normal controls. Gastroenterol Res Pract. 2013;2013:498296

44.              Noureddin M*, Yates KP, Vaughn IA, Neuschwander-Tetri BA, Sanyal AJ, McCullough A, Merriman R, Hameed B,  Doo E, Kleiner DE, Behling C, and Loomba R for the NASH CRN. Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients. Hepatology 2013.Nov; 58 (5):1644-54

45.              Loomba R, Liu J, Yang HI, Lee MH, Lu SN, Wang LY, Iloeje UH, You SL, Brenner D, Chen CJ. Synergistic Effects of Family History of Hepatocellular Carcinoma and Hepatitis B Virus Infection on Risk for Incident Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2013 Dec;11(12):1636-1645.

46.              Noureddin M*, Lam J, Peterson M, Middleton M, Hamilton G, Le TA, Changchien C, David A. Brenner DA, Sirlin C, and Loomba R. Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology. 2013 Dec;58(6):1930-40.

47.              Doycheva I* and Loomba R. Effect of metformin on ballooning degeneration in NASH: When to use metformin in NAFLD. Adv Ther. 2014 Jan;31(1):30-43

48.              Johnson BL, Schroeder ME, Wolfson T, Gamst AC, Hamilton G, Shiehmorteza M, Loomba R, Schwimmer JB, Reeder S, Middleton MS, Sirlin CB. Effect of flip angle on the accuracy and repeatability of hepatic proton density fat fraction estimation by complex data-based, T1-independent, T2*-corrected, spectrum-modeled MRI. J Magn Reson Imaging. 2014 Feb; 39(2):440-7

49.              Yang L, Roh YS, Song J, Zhang B, Liu C, Loomba R, Seki E. Transforming growth factor beta signaling in hepatocytes participates in steatohepatitis through regulation of cell death and lipid metabolism in mice. Hepatology. 2014 Feb;59(2):483-95

50.              Stinton L* and Loomba R. Recommendations for liver biopsy evaluation in nonalcoholic fatty liver disease. Minerva Gastroenterol Dietol. 2014 Mar;60(1):5-13

51.              Levin YS, Yokoo T, Wolfson T, Gamst AC, Collins J, Achmad EA, Hamilton G, Middleton MS, Loomba R, Sirlin CB. Effect of echo-sampling strategy on the accuracy of out-of-phase and in-phase multiecho gradient-Echo MRI hepatic fat fraction estimation. J Magn Reson Imaging. 2014 Mar;39(3):567-75

52.              Boland BS*, Dong MH*, Bettencourt R, Barrett-Connor E, and Loomba R. Association of serum bilirubin with aging and mortality. J Clin Exp Hepatol. 2014;4:1–7

53.              Rinella ME, Loomba R, Caldwell SH, Kowdley K, Charlton M, Tetri B, Harrison SA. Controversies in the Diagnosis and Management of NAFLD and NASH. Gastroenterol Hepatol. 2014 Apr;10(4):219-27.

54.              Negrete LM, Middleton MS, Clark L, Wolfson T, Gamst AC, Lam J, Changchien C, Deyoung-Dominguez IM, Hamilton G, Loomba R, Schwimmer J, Sirlin CB. Inter-examination precision of magnitude-based MRI for estimation of segmental hepatic proton density fat fraction in obese subjects. J Magn Reson Imaging. 2014 May;39(5):1265-71

55.              Pearlman M* and Loomba R. State of the art: Treatment of nonalcoholic steatohepatitis. Curr Opin Gastroenterol. 2014 May;30(3):223-37

56.              Bonekamp S, Tang A, Mashhood A, Wolfson T, Changchien C, Middleton MS, Clark L, Gamst A, Loomba R, Sirlin CB. Spatial distribution of MRI-determined hepatic proton density fat fraction in adults with nonalcoholic fatty liver disease. J Magn Reson Imaging. 2014 Jun;39(6):1525-32

57.              Bambha K, Wilson LA, Unalp A, Loomba R, Neuschwander‐Tetri BA, Brunt EM, Bass NM for the NASH CRN. Coffee Consumption in NAFLD Patients with Lower Insulin Resistance is Associated with Lower Risk of Severe Fibrosis. Liver Int. 2014 Sep;34(8):1250-8

58.              Joshi K, Mendler M, Gish R, Loomba R, Kuo A, Patton H, Kono Y. Hepatocellular Carcinoma Surveillance: A National Survey of Current Practices in the USA. Dig Dis Sci. 2014 Dec;59(12):3073-7.

59.              Vuppalanchi R, Jain AK, Deppe R, Yates K, Comerford M, Masuoka HC, Neuschwander-Tetri BA, Loomba R, Brunt EM, Kleiner DE, Molleston JP, Schwimmer JB, Lavine JE, Tonascia J, Chalasani N. Relationship Between Changes in Serum Levels of Keratin 18 and Changes in Liver Histology in Children and Adults with Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol.2014 Dec;12(12):2121-2130.

60.              Loomba R, Wolfson T, Ang B, Booker J, Behling C, Peterson M, Valasek M, Lin G, Brenner D, Gamst A, Ehman R, Sirlin C. Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: A prospective study. Hepatology 2014 Dec;60(6):1920-8.

61.              Tang A, Chen J, Le TA*, Changchien C, Hamilton G, Middleton MS, Loomba R, Sirlin CB. Cross-sectional and longitudinal evaluation of liver volume and total liver fat burden in adults with nonalcoholic steatohepatitis. Abdom Imaging. 2015 Jan;40(1):26-37.

62.              Singh S*, Allen AM*, Wang Z, Prokop LJ, Murad MH, and Loomba R. Fibrosis Progression in Nonalcoholic Fatty Liver versus Nonalcoholic Steatohepatitis: A Systematic Review and Meta-analysis of Paired-Biopsy Studies. Clin Gastroenterol Hepatol. 2015 Apr;13(4):643-654.

63.              Patel NS, Doycheva I, Peterson MR, Hooker J, Kisselva T, Schnabl B, Seki E, Sirlin CB, and Loomba R. Effect of Weight Loss on MRI Estimation of Liver Fat and Volume in Patients With Nonalcoholic Steatohepatitis. Clinical Gastroenterology and Hepatology. 2015 Mar; 13(3): 561-568.

64.              Chen P, Torralba M, Tan J, Embree M, Zengler K, Stärkel P, Pijkeren JP, DePew J, Loomba R, Ho SB, Bajaj JS, Mutlu EA, Keshavarzian A, Tsukamoto H, Nelson KE, Fouts DE, Schnabl B. Supplementation of Saturated Long-chain Fatty Acids Maintains Intestinal Eubiosis and Reduces Ethanol-induced Liver Injury in Mice. Gastroenterology. 2015 Jan; 148(1):203-214.

65.              Tang A, Desai A, Hamilton G, Wolfson T, Gamst A, Lam J, Clark L, Hooker J, Chavez T, Ang BD, Middleton MS, Peterson M, Loomba R, Sirlin CB. Accuracy of MR Imaging-estimated Proton Density Fat Fraction for Classification of Dichotomized Histologic Steatosis Grades in Nonalcoholic Fatty Liver Disease. Radiology. 2015 Feb;274(2):416-25

66.              Murphy P, Hooker J, Ang B, Wolfson T, Gamst A, Bydder M, Middleton M, Peterson M, Behling C, Loomba R, Sirlin C. Associations between histologic features of nonalcoholic fatty liver disease (NAFLD) and quantitative diffusion-weighted MRI measurements in adults. J Magn Reson Imaging. 2015 Jun; 41(6): 1629-38.

67.              Loomba R, Quehenberger O, Amado A, Dennis EA. Polyunsaturated fatty acid metabolites as novel lipidomic biomarkers for noninvasive diagnosis of nonalcoholic steatohepatitis. Journal of Lipid Research 2015 Jan; 56(1):185-92.

68.              Vodkin I*, Bettencourt R, Valasek MV, Cachay E, Loomba R.  Clinical, biochemical and histologic differences between HIV-associated NAFLD and primary NAFLD: a case-control study. Aliment Pharmacol Ther. 2015 Feb;41(4):368-78

69.              Lin SC*,  Heba E, Wolfson T, Ang B, Gamst A, Han A,  Erdman Jr. JW, O'Brien Jr. WD, Andre MP, Sirlin CB, and Loomba R. Noninvasive diagnosis of nonalcoholic fatty liver disease and quantification of liver fat by new quantitative ultrasound. Clinical Gastroenterology and Hepatology 2015 Jul; 13(7): 1337-1345.

70.              Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF Chalasani N, Dasarathy S, Diehl AM, Hameed B, Kowdley KV, McCullough A, Terrault N, Clark JM, Tonascia J, Brunt EM, Kleiner DE, Doo E. Farsenoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015 Mar 14;385(9972):956-65.

71.              Loomba R, Sirlin C, Ang B, Bettencourt R, Jain R*, Salotti J, Soaft L, Hooker J, Kono Y, Bhatt A, Hernandez L, Nguyen P, Noureddin M*, Haufe W, Hooker C, Yin M, Ehman R, Lin G, Valasek M, Brenner D, Richards L. Ezetimibe for the treatment of nonalcoholic steatohepatitis: Assessment by novel MRI and MRE in a randomized trial (MOZART Trial). Hepatology. 2015 Apr;61(4):1239-50.

72.              Zarrinpar A, Gupta S, Maurya MR, Subramaniam S, Loomba R. Serum microRNAs explain discordance of non-alcoholic fatty liver disease in monozygotic and dizygotic twins: a prospective study. Gut 2015 May 22. pii. Gutjnl-2015-309456.

73.              Arulanandan A*, Ang B, Bettencourt R, Hooker J, Behling C, Lin GY, Valasek MA, Ix JH, Schnabl B, Sirlin CB, Loomba R. Association Between Quantity of Liver Fat and Cardiovascular Risk in Patients with Nonalcoholic Fatty Liver Disease Independent of Nonalcoholic Steatohepatitis. Clinical Gastroenterology and Hepatology 2015 Aug; 13(8): 1513-20.

74.              Cui J*, Ang B, Haufe W, Hernandez C, Verna EC, Sirlin CB, Loomba R. Comparative diagnostic accuracy of magnetic resonance elastography vs. eight clinical prediction rules for non-invasive diagnosis of advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease: a prospective study. Aliment Pharmacol Ther. 2015 Jun; 41(12):1271-80.

75.              Arulanandan A. Loomba R. Noninvasive Testing for NASH and NASH with Advanced Fibrosis: Are We There Yet? Current Hepatology Reports. 2015(14); 109-18.

76.              Bazick J*, Donithan M, Neuschwander-Tetri BA, Kleiner D, Brunt EM, Wilson L, Doo E, Lavine J, Tonascia J, Loomba R. Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD. Diabetes Care. 2015 Jul; 38(7):1347-55.

77.              Wanner A,  Groft SC, Teagarden JR, Krischer J, Davis BR, Coffey CS, Hickam, Teckman J, Nelson DR, McCaleb M, Loomba R, Strange C, Sandhaus RA, Brantly M, Edelman JM, Farrugia A. Clinical Trial Design for Alpha-1 Antitrypsin Deficiency: A Model for Rare Diseases. Journal of COPD Foundation. 2015; 2(2): 177-190.

78.              Roh YS, Zhang B, Loomba R, Seki E. TLR2 and TLR9 contribute to alcohol-mediated liver injury through induction of CXCL1 and neutrophil infiltration. Am J Physiol Gastrointest Liver Physiol. 2015 Jul 1; 309(1):G30-41.

79.              Verna EC, Patel J, Bettencourt R, Nguyen P, Hernandez C, Valasek MA, Kisselva T, Brenner DA, Loomba R. Novel association between serum pentraxin-2 levels and advanced fibrosis in well-characterised patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2015 Sep;42(5):582-90.

80.              Halldorson J, Kazi Z, Mekeel K, Kuo A, Hassanein T, Loomba R, Austin S, Valasek MA, Kishnani P, Hemming AW. Successful combined liver/kidney transplantation from a donor with Pompe disease. Mol Genet Metab. 2015 Aug; 115(4):141-4.

81.              Spengler E*, Loomba R. Recommendations for Diagnosis, Referral for Liver Biopsy and Treatment of NAFLD and NASH. Mayo Clinic Proceedings. 2015 Sep; 90(9): 1233-46.

82.              Hamilton G, Middleton MS, Hooker JC, Haufe WM, Forbang NI, Allison MA, Loomba R, Sirlin CB. In vivo breath-hold 1 H MRS simultaneous estimation of liver proton density fat fraction, and T1 and T2 of water and fat, with a multi-TR, multi-TE sequence. J Magn Reson Imaging. 2015 Dec; 42(6): 1538-43.

83.              Singh S*, Murad MH, Chandar AK, Bongiorno CM, Singal AK, Atkinson SR, Thursz MR, Loomba R, Shah VH. Comparative Effectiveness of Pharmacological Interventions for Severe Alcoholic Hepatitis: A Systematic Review and Network Meta-analysis. Gastroenterology. 2015 Oct; 149(4): 958-70.

84.              Kim WR, Loomba R, Berg T, Aguilar Schall RE, Yee LJ, Dinh P, Flaherty JF, Martins EB, Therneau TM, Jacobson I, Fung S, Gurel S, Buti M, Marcellin P. Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B. Cancer. 2015 Oct 15; 121(20): 3631-8.

85.              Singh S*, Khera R, Wang Z, Prokop LJ, Murad MH, and Loomba R. Comparative Effectiveness of Pharmacological Interventions for Non-alcoholic Steatohepatitis: A Systematic Review and Network Meta-analysis. Hepatology. 2015 Nov 12; 10(6): 552-60.

86.              Singh S*, Venkatesh SK, Loomba R, Wang Z, Sirlin C, Chen J, Yin M, Miller FH, Low RN, Hassanein T, Godfrey EM, Asbach P, Murad MH, Lomas DJ, Talwalkar JA, Ehman RL. Magnetic resonance elastography for staging liver fibrosis in non-alcoholic fatty liver disease: a diagnostic accuracy systematic review and individual participant data pooled analysis. Euro Radiology. 2016 May; 26(5): 1431-40.

87.              Loomba R, Schork N, Chen CH, Bettencourt R, Bhatt A, Ang B, Nguyen P, Hernandez C, Richards L, Salotti J, Lin S*, Seki E, Nelson KE, Sirlin CB, Brenner D; Genetics of NAFLD in Twins Consortium. Gastroenterology. 2015 Dec; 149(7): 1784-93.

88.              Mencin AA, Loomba R, Lavine JE. Caring for the children with NAFLD and navigating their care into adulthood. Nat Rev Gastroenterology and Hepatology. 2015 Nov; 12(11): 617-28.

89.              Tyagi A, Yeganeh O, Levin Y, Hooker JC, Hamilton GC, Wolfson T, Gamst A, Zand AK, Heba E, Loomba R, Schwimmer J, Middleton MS, Sirlin CB. Intra- and inter-examination repeatability of magnetic resonance spectroscopy, magnitude-based MRI, and complex-based MRI for estimation of hepatic proton density fat fraction in overweight and obese children and adults. Abdominal Imaging 2015 Oct; 40(8): 3070-7.

90.              Doycheva I*, Cui J*, Nguyen P, Costa EA, Hooker J, Hofflich H, Bettencourt R, Brouha S, Sirlin CB, Loomba R. Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE. Aliment Pharmacol Ther. 2016 Jan 43(1): 83-95.

91.              Rinella ME, Lominadze Z, Loomba R, Charlton M, Neuschwander-Tetri BA, Caldwell SH, Kowdley K and Harrison SA. Practice patterns in NAFLD and NASH: Real life differs from published guidelines. Therapeutic Advances in Gastroenterology 2016 Jan; 9(1): 4-12.

92.              Cui J*, Heba E, Hernandez C, Haufe W, Hooker J, Andre MP, Valasek MA, Aryafar H, Sirlin CB, Loomba R. MRE is superior to ARFI for the diagnosis of fibrosis in patients with biopsy-proven NAFLD: A prospective study. Hepatology. 2016 Feb: 63(2): 453-61.

93.              Jacobs K, Brouha S, Bettencourt R, Barrett-Connor E, Sirlin CB and Loomba R. Nonalcoholic Fatty Liver Disease, Visceral Adiposity and Coronary Artery Calcification in the Elderly. Clinical Gastroenterology and Hepatology 2016 Jan 25. pii: S1542-3565(16) 00053-7.

94.              Anand G*, Zarrinpar A, Loomba R. Targeting Dysbiosis for the Treatment of Liver Disease. Semin Liver Dis. 2016 Feb; 36(1):37-47.

95.              Schnabl B, Farshchi-Heydari S, Loomba R, Mattrey RF, Hoh CK, Sirlin CB, Brenner DA, Behling CA, Vera DR. Staging of Fibrosis in Experimental Non-Alcoholic Steatohepatitis by Quantitative Molecular Imaging in Rat Models. Nucl Med Biol. 2016 Feb;43(2):179-87.

96.              Heba ER, Desai A, Zand KA, Hamilton G, Wolfson T, Schlein AN, Gamst A, Loomba R, Sirlin CB, Middleton MS. Accuracy and the Effect of Possible Subject- Based MRI for estimating Hepatic Proton Density Fat Fraction in Adults, Using MR Spectroscopy as Reference. J Magn Reson Imaging. 2016 Feb;43(2):398-406.

97.              Lin SC, Ang B, Hernandez C, Bettencourt R, Jain R, Salotti J, Richards L, Kono Y, Bhatt A, Aryafar H, Lin GY, Valasek MA, Sirlin CB, Brouha S, and Loomba R. Cardiovascular risk assessment in the treatment of nonalcoholic steatohepatitis: a secondary analysis of the MOZART trial. Therap Adv. Gastroenterology. 2016 Mar 9: 152-61.

98.              Ray Kim W, Berg T, Asselah T, Flisiak R, Fung S, Gordon SC, Janssen HL, Lampertico P, Lau D, Bornstein JD, Aguilar Schall RE, Dinh P, Yee LJ, Martins EB, Lim SG, Loomba R, Petersen J, Buti M, Marcellin P. Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients. Journal of Hepatology 2016 Apr; 64(4): 773-80.

99.              Singh S, Venkatesh SK, Loomba R, Wang Z, Sirlin C, Chen J, Yin M, Miller FH, Low RN, Hassanein T, Godfrey EM, Asbach P, Murad MH, Lomas DJ, Talwalkar JA, Ehman RL. Magnetic Resonance Elastography for Staging Liver Fibrosis in Non- Alcoholic Fatty Liver Disease: A diagnostic Accuracy Systematic Review and Individual Participant Data Pooled Analysis. Eur Radiol. 2016 May;26(5):1431-40.

100.          Jayakumar S, Harrison SA, Loomba R. Noninvasive Marjers of Fibrosis and Inflamation in Nonalcoholic Fatty Liver Disease. Curr Hepatol Rep. 2016 Jun;15(2):86-95.

101.          Noureddin M, Anstee QM, Loomba R. Review: Emerging Anti-Fibrotic Therapies in the Treatment of Non-Alcoholic Steatohepatitis. Aliment Pharmacol Ther. 2016 Jun;43(11):1109-23

102.          Loomba R, Cui J, Wolfson T, Haufe W, Hooker J, Szeverenyi N, Ang B, Bhatt, Wang K, Aryafar H, Behling C, Valasek MA, Lin GY, Gamst A, Brenner DA, Yin M, Glaser KJ, Ehman RL, and Sirlin CB. Novel 3D Magnetic Resonance Elastography for the Noninvasive Diagnosis of Advanced Fibrosis in NAFLD: A Prospective study. Am J Gastronterol. 2016 Jul;111(7):986-94.

103.          Cui J, Philo L, Nguyen P, Hofflich H, Hernandez C, Bettencourt R, Richards L, Salotti J, Bhatt A, Hooker J, Haufe W, Hooker C, Brenner DA, Sirlin CB, Loomba R. Sitagliptin versus placebo in the treatment of nonalcoholic fatty liver disease: A randomized controlled trial. J Hepatol. 2016. Aug;65 (2):369-76.

104.          Kim RG, Nguyen P, Bettencourt R, Dulai PS, Haufe W, Hooker J, Minocha J, Valasek MA, Aryafar H, Brenner DA, Sirlin CB, Loomba R. Magnetic resonance elastography identifies fibrosis in adults with alpha-1 antitrypsin deficiency liver disease: a prospective study. Aliment Pharmacol Ther. 2016 Aug;44(3):287-99

105.          Khera R, Murad MH, Chandar AK, Dulai PS, Wang Z, Prokop LJ, Loomba R, Camilleri M, Singh S. Association of Pharmacological Treatments for Obesity with Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. JAMA. 2016 Jun 14;315(22):2424-34.

106.          Noureddin M, Zhang A, Loomba R. Promising therapies for treatment of nonalcoholic steatohepatitis. Expert Opin Emerg Drugs. 2016 Aug 28:1-15.

107.          Patel J, Bettencourt R, Cui J, Salotti J, Hooker J, Bhatt A, Hernandez C, Nguyen P, Aryafar H, Valasek M, Haufe W, Hooker C, Richards L, Sirlin CB, Loomba R. Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis. Therap Adv Gastroenterol. 2016 Sep;9(5):692-701

108.          Dulai PS, Sirlin CB, Loomba R. MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice. J Hepatol. 2016 Nov;65(5):1006-1016

109.          Cui J, Chen CH, Lo MT, Schork N, Bettencourt R, Gonzalez MP, Bhatt A, Hooker J, Shaffer K, Nelson KE, Long MT, Brenner DA, Sirlin CB, Loomba R. Shared genetic effects between hepatic steatosis and fibrosis: A prospective twin study. Hepatology 2016. Nov;64(5):1547-1558

110.          Ajmera V, Perito ER, Bass NM, Terrault NA, Yates KP, Gill R, Loomba R, Diehl AM, Aouizerat BE. NASH Clinical Research Network. Novel Plasma Biomarker Associated with Liver Disease Severity in Adults with Nonalcoholic Fatty Liver Disease. Hepatology. 2016 [Epub ahead of print]

111.          Hamilton G, Schlein AN, Middleton MS, Hooker CA, Wolfson T, Gamst AC, Loomba R, Sirlin CB. In Vivo Triglyceride Composition of Abdominal Adipose Tissue Measured by 1H MRS at 3T. J Magn Reson Imaging. 2016 [Epub ahead of print]

112.          Patel NS, Hooker J, Gonzalez M, Bhatt A, Nguyen P, Ramirez K, Richards L, Rizo E, Hernandez C, Kisseleva T, Schnabl B, Brenner D, Sirlin CB, Loomba R. Weight Loss Decreases Magnetic Resonance Elastography Estimated Liver Stiffness in Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2016 Oct 3. [Epub ahead of print]

113.          Decaris ML, Li KW, Emson CL, Gatmaitan M, Liu S, Wang Y, Nyangau E, Colangelo M, Angel TE, Beysen C, Cui J, Hernandez C, Lazaro L, Brenner DA, Turner SM, Hellerstein MK, Loomba R. Identifying NAFLD Patients with Active Fibrosis by Measuring Extracellular Matrix Remodeling Rates in Tissue and Blood. Hepatology. 2016 [Epub ahead of print]

114.          Park CP, Nguyen P, Hernandez C, Bettencourt R, Ramirez K, Fortney L, Hooker J, Sy E, Alquiraish MH, Valasek MA, Rizo E, Richards L, Brenner DA, Sirlin CB, Loomba R. Magnetic Resonance Elastography vs Transient Elastography in Detection of Fibrosis and Noninvasive Measurement of Steatosis in Patients with Biopsy-proven Nonalcoholic Fatty Liver Disease. Gastroenterology 2016. Published online October 27. [Epub ahead of print]


  1. Stinton L*, Loomba R. Dissecting the PNPLA3 association with liver fat and stiffness, and interaction with diet. Aliment Pharmacol Ther. 2014 Apr;39(8):894-5
  2. Loomba R. Serum alanine aminotransferase as a biomarker of treatment response in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2014 Oct;12(10):1731-2
  3. Loomba R. Rationale for conducting randomized trial to examine the efficacy of metformin in improving survival in cirrhosis: Pleiotropic effects hypothesis. Hepatology 2014 Dec;60(6):1818-22
  4. Roh YS, Loomba R, Seki E. The TM6SF2 Variants, Novel Genetic Predictors for Nonalcoholic Steatohepatitis. Gastroenterology 2015 Jan;148(1):252-4
  5. Spengler EKJ*, Loomba R. Gut microbiome, Intestinal permeability, bacterial translocation and NAFLD. In press Cellular and Molecular Gastroenterology and Hepatology 2015
  6. Verna EC, Loomba R. Call to screen for NAFLD and NASH in psoriasis. Aliment Pharmacol Ther. 2015 Mar;41(5):492-3
  7. Loomba R, Cortez-Pinto H. Exercise and improvement of NAFLD: Practical recommendations. J Hepatol. 2015 Jul;63(1):10-2.
  8. Konerman M, Loomba R. Diabetes and its association with hepatocellular carcinoma in chronic hepatitis B. Aliment Pharmacol Ther. 2015 Jul;42(1):117-8
  9. Loomba R, Chalasani N. The Hierarchical Model of NAFLD: Prognostic Significance of Histologic Features in NASH. Gastroenterology. 2015 Aug;149(2):278-81
  10. Singh S and Loomba R. Obesity in chronic liver diseases - increased infections. Aliment Pharmacol Ther. 2016 Jan;43(2):311-2
  11. Kishore R, Loomba R, Sterling RK. Editorial: A New Spin on Magnetic Resonance Elastography. Am J Gastroenterol. 2016 Jun;111(6):834-7
  12. Konerman MA, Loomba R. Editorial: the burden and aetiology of liver cirrhosis, and the risk of death. Aliment Pharmacol Ther. 2016 Jul;44(2):202-3
  13. Malhi H, Loomba R. Editorial: dark chocolate may improve NAFLD and metabolic syndrome by reducing oxidative stress. Aliment Pharmacol Ther. 2016 Sep;44(5):533-4
  14. Venkatesh SK, Loomba R. Non-invasive estimation of HVPG by combined structural and hemodynamic evaluation of portal hypertension using quantitative magnetic resonance imaging. J Hepatology 2016 [Epub ahead of print]